Treatment target for aggressive leukemia discovered by disrupting its genome organization
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Bone Marrow Donors Can Be Hard to Find. One Company Is Turning to Cadavers
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
Grandmother, 1-year-old granddaughter battle cancer together
Across the street from MD Anderson, at Texas Children's Hospital, Fivecoat's then-nearly 1-year-old granddaughter Whitney was ...
Study reveal single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Business Insider2d
Sanofi treatment of acute myeloid leukemia granted orphan status
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...